|Bid||2.32 x 1300|
|Ask||2.51 x 600|
|Day's Range||2.41 - 2.47|
|52 Week Range||1.82 - 7.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
Sunesis Pharmaceuticals, Inc. (SNSS) today announced three key new management appointments as part of the Company’s expansion of its development team. Deepali Suri, M.Sc., a former Executive Director at Pharmacyclics (an AbbVie Company), was appointed Vice President, Clinical Operations, and Sean Gharpurey, M.S., MBA, joined as Executive Director, Project Management. Stephen Nava was promoted to Vice President, Quality Assurance, Compliance and Regulatory Affairs.
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it has entered into a Common Shares Purchase Agreement (the “Agreement”) of up to $15.5 million with Aspire Capital Fund, LLC (“Aspire Capital”). Under the terms of the Agreement, Aspire Capital has made an initial investment via purchase of $500,000 worth of SNSS common shares at a price of $2.19 per common share. In addition, Aspire Capital has committed to purchasing up to an additional $15 million of common shares of Sunesis, at Sunesis’ request from time to time during a 24-month period beginning on the effective date of a registration statement related to the transaction and at prices based on the market price at the time of each sale.
Université Claude Bernard de Lyon Study Provides Preclinical Validation of Vecabrutinib Activity Against Ibrutinib-Resistant BTK C481S Mutated Lymphomas. ERIC Study Shows Half of Ibrutinib-Relapse CLL ...
The South San Francisco, California-based company said it had a loss of 21 cents per share. The biopharmaceutical company posted revenue of $237,000 in the period. In the final minutes of trading on Tuesday, ...
Sunesis to Host Conference Call Today at 4:30 PM Eastern Time. SOUTH SAN FRANCISCO, Calif., May 08, 2018-- Sunesis Pharmaceuticals, Inc. today reported financial results for the first quarter ended March ...
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it will host a conference call on Tuesday, May 8th, 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2018. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
Investors in Sunesis Pharmaceuticals (SNSS) need to pay close attention to the stock based on moves in the options market lately.
The South San Francisco, California-based company said it had a loss of 21 cents per share. For the year, the company reported that its loss narrowed to $35.5 million, or $1.45 per share. Revenue was reported ...
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 4:30 PM Eastern ...
On Thursday, Sunesis Pharmaceuticals (NASDAQ: SNSS ) will report its last quarter's earnings. Here is Benzinga's take on the company's release. Earnings and Revenue Sunesis Pharmaceuticals EPS loss will ...
Measuring Sunesis Pharmaceuticals Inc’s (NASDAQ:SNSS) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations,Read More...
LONDON, UK / ACCESSWIRE / November 16, 2017 / Sunesis (NASDAQ: SNSS) remains on track to complete the dose-escalation portion of its Phase Ib/II clinical trial for lead compound SNS-062, an oral Bruton's ...